January review for Lifecore's surgical gel:
This article was originally published in Clinica
Executive Summary
An FDA advisory panel will review Lifecore Biomedical's premarket approval (PMA) application for its Intergel adhesion prevention gel on January 12. The gel is designed to prevent surgical adhesions following gynaecological laparotomy and laparoscopy, with laparotomy procedures being the subject of the first PMA. The Chaska, Minnesota-based company will submit data from its laparoscopy clinical trial as a supplement to the PMA at a later date.
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.